Tradestie Institutional Equity Comparison Engine
ABBV vs MTNB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABBV Overall Edge
ABBV Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Abbvie Inc. (ABBV) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ABBV trades at 17.4x Forward P/E with 36.6% operating margin (+10.3% YoY revenue) versus MTNB at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, ABBV sits in CONSOLIDATION (12th %ile IV; Dealer Gamma Walls on Pro) against MTNB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
ABBV
ABBV 17.4x vs MTNB N/M Fwd P/E
Growth & Margin Winner
ABBV
Op Margin 36.6% vs 0.0% ยท YoY +10.3% vs -100.0%
Momentum & Technical Winner
ABBV
1Y +21.2% vs -31.4% ยท 52W Pos 83% vs 22%
Options & Structure Winner
ABBV
CONSOLIDATION (12th %ile IV) vs UNCLASSIFIED (N/A IV)
ABBV
NYSE
Abbvie Inc.
Pharmaceutical Preparations
$283.54
-0.86% 1D
Market Cap
$505.6B
1M Return
-0.44%
1Y Return
+21.24%
Forward P/E
17.4x
Unified AI Score
53.5 / 100
HOLD
Tech 42.0
Fund 46.0
Flow 72.0
Mom 21.1
MTNB
NYSE American
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations
$0.81
-10.98% 1D
Market Cap
$979,904
1M Return
-46.7%
1Y Return
-31.35%
Forward P/E
N/M
Unified AI Score
54.6 / 100
HOLD
Tech 53.0
Fund 58.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ABBV +21.24%
MTNB -31.35%
Spread: +52.59 pp (ABBV Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ABBV Revenue | MTNB Revenue | ABBV Op. Margin | MTNB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $32.8B | $0M | 19.5% | -12230.9% | ABBV |
| FY2019 | $33.3B | $0M | 39.0% | -21067.4% | ABBV |
| FY2020 | $45.8B | $0M | 24.8% | -15288.4% | ABBV |
| FY2021 | $56.2B | $0M | 31.9% | -74954.5% | ABBV |
| FY2022 | $58.0B | $0M | 31.2% | -771.3% | ABBV |
| FY2023 | $54.3B | $0M | 23.5% | -2168.4% | ABBV |
| FY2024 | $56.3B | N/A | 16.2% | N/A | ABBV |
| FY2025 | $61.2B | N/A | 24.6% | N/A | ABBV |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ABBV | MTNB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $505.6B | $979,904 | Larger Scale | ABBV |
| Trailing P/E Ratio Valuation | 49.1x | N/M | Lower Multiple | ABBV |
| Forward P/E Ratio Valuation | 17.4x | N/M | Lower Multiple | ABBV |
| Revenue Growth (YoY) Growth | +10.3% | -100.0% | Higher Growth | ABBV |
| Operating Margin (TTM) Profitability | 36.6% | 0.0% | Higher Margin | ABBV |
| Net Profit Margin Profitability | 15.7% | 0.0% | Higher Margin | ABBV |
| Return on Equity (ROE) Capital Efficiency | 62.3% | -147.5% | Higher ROE | ABBV |
| 52-Week Range Position Momentum | 83% ($191โ$303) | 22% ($0โ$3) | Stronger Trend | ABBV |
| Beta / 30D Volatility Risk Regime | -0.02ฮฒ ยท 20% Vol | -7.20ฮฒ ยท 147% Vol | Lower Realized Risk | ABBV |
| Unified Institutional Score Composite Signal | 53.5 / 100 (HOLD) | 54.6 / 100 (HOLD) | Higher Composite | MTNB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ABBV vs MTNB Buy Guide
ABBV
CONSOLIDATION
98d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
12th %ile
IV Regime
Compressed (<25th %ile)
MTNB
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ABBV nor MTNB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.